Item 7.01 Regulation FD Disclosure On February 9, 2026, Biofrontera Inc. issued a press release announcing the results in its Phase 3 study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk. The full text of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.…
Filed Feb 9, 2026Accepted Feb 9, 2026, 9:20 AM ESTCIK 1858685Accession 0001493152-26-005717
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure
On
February 9, 2026, Biofrontera Inc. issued a press release announcing the results in its Phase 3 study of Ameluz® PDT for Actinic
Keratoses on the Extremities, Neck, and Trunk. The full text of the press release is furnished herewith as Exhibit 99.1 and
is incorporated herein by reference.
The
information contained in Item 7.01 of this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing by the company under the Securities Act of 1933 or the
Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm
Exhibit 99.1
Biofrontera
Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck,
and Trunk, Meeting Primary Endpoint
Study
findings met its primary endpoint and showed highly statistically significant superiority for Ameluz® vs. vehicle gel
(p<0.0003)
Actinic
keratosis (AK) is the most common skin condition diagnosed by US dermatologists1
If
left untreated, AK may progress to squamous cell carcinoma2,3
WOBURN,
Mass. (February 9, 2026) - Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical
company specializing in the development and commercialization of photodynamic therapy (PDT), today announced positive and statistically
significant top-line results from its Phase 3 clinical trial evaluating Ameluz ® PDT with the red-light LED (RhodoLED ® )
platform for the treatment of mild to moderate actinic keratoses (AKs) on the extremities, neck, and trunk.
The
multicenter, randomized, double-blind, vehicle-controlled Phase 3 study evaluated the efficacy and tolerability of field-directed Ameluz ® PDT compared with vehicle PDT in patients with AKs located on the extremities, neck, and trunk.…